Acute Myeloid Leukemia Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Acute Myeloid Leukemia pipeline constitutes 260+ key companies continuously working towards developing 260+ Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Acute Myeloid Leukemia Overview
Acute Myeloid Leukemia (AML) is a type of blood cancer. Also known as Acute myeloid leukemia (AML), it starts in the bone marrow and moves into the blood. AML sometimes spreads into the other parts of the body including the lymph nodes, liver, spleen, central nervous system and testicles. AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells.

The main treatment for most types of Acute Myeloid Leukemia (AML) is chemotherapy, sometimes along with a targeted therapy drug. This might be followed by a stem cell transplant.

"Acute Myeloid Leukemia Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Myeloid Leukemia Market.

The Acute Myeloid Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acute Myeloid Leukemia Pipeline Report: https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Acute Myeloid Leukemia treatment therapies with a considerable amount of success over the years. Acute Myeloid Leukemia Key players such as - Aptose Biosciences Inc., BioTheryX, Inc., Kartos Therapeutics, AB Science, BioSight, DCPrime, Gilead Sciences, GlycoMimetics, AROG Pharmaceuticals, and others, are developing therapies for the Acute Myeloid Leukemia treatment
• Acute Myeloid Leukemia Emerging therapies such as - CG-806, BTX-A51, KRT-232, AB8939, BST 236, DCP-001, Magrolimab, Uproleselan, Crenolanib, and others are expected to have a significant impact on the Acute Myeloid Leukemia market in the coming years.
• In October 2018, GlycoMimetics initiated a Phase III study to evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone

Acute Myeloid Leukemia Pipeline Therapeutics Assessment
• Acute Myeloid Leukemia Assessment by Product Type
• Acute Myeloid Leukemia By Stage and Product Type
• Acute Myeloid Leukemia Assessment by Route of Administration
• Acute Myeloid Leukemia By Stage and Route of Administration
• Acute Myeloid Leukemia Assessment by Molecule Type
• Acute Myeloid Leukemia by Stage and Molecule Type

DelveInsight's Acute Myeloid Leukemia Report covers around 260+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Acute Myeloid Leukemia Drugs Under Different Phases of Clinical Development Include:
• CG-806: Aptose Biosciences Inc.
• BTX-A51: BioTheryX, Inc.
• KRT-232: Kartos Therapeutics
• AB8939: AB Science
• BST 236: BioSight
• DCP-001: DCPrime
• Magrolimab: Gilead Sciences
• Uproleselan: GlycoMimetics
• Crenolanib: AROG Pharmaceuticals

Get a Free Sample PDF Report to know more about Acute Myeloid Leukemia Pipeline Assessment-
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Myeloid Leukemia Pipeline Analysis:

The Acute Myeloid Leukemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Acute Myeloid Leukemia treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia Treatment.
• Acute Myeloid Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Acute Myeloid Leukemia product details are provided in the report. Download the Acute Myeloid Leukemia pipeline report to learn more about the emerging Acute Myeloid Leukemia therapies at:
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Myeloid Leukemia Pipeline Market Drivers
• Increasing prevalence of Acute Myeloid Leukemia patients
• Increasing novel drug therapy pipeline

Acute Myeloid Leukemia Pipeline Market Barriers
• High cost of therapies entering the market
• Side-effects and relapse after chemotherapy

Scope of Acute Myeloid Leukemia Pipeline Drug Insight
• Coverage: Global
• Key Acute Myeloid Leukemia Companies: Aptose Biosciences Inc., BioTheryX, Inc., Kartos Therapeutics, AB Science, BioSight, DCPrime, Gilead Sciences, GlycoMimetics, AROG Pharmaceuticals, and others
• Key Acute Myeloid Leukemia Therapies: CG-806, BTX-A51, KRT-232, AB8939, BST 236, DCP-001, Magrolimab, Uproleselan, Crenolanib, and others
• Acute Myeloid Leukemia Therapeutic Assessment: Acute Myeloid Leukemia current marketed and Acute Myeloid Leukemia emerging therapies
• Acute Myeloid Leukemia Market Dynamics: Acute Myeloid Leukemia market drivers and Acute Myeloid Leukemia market barriers

Request for Sample PDF Report for Acute Myeloid Leukemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Acute Myeloid Leukemia Report Introduction
2 Acute Myeloid Leukemia Executive Summary
3 Acute Myeloid Leukemia Overview
4 Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment
5 Acute Myeloid Leukemia Pipeline Therapeutics
6 Acute Myeloid Leukemia Late Stage Products (Phase II/III)
7 Acute Myeloid Leukemia Mid Stage Products (Phase II)
8 Acute Myeloid Leukemia Early Stage Products (Phase I)
9 Acute Myeloid Leukemia Preclinical Stage Products
10 Acute Myeloid Leukemia Therapeutics Assessment
11 Acute Myeloid Leukemia Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Acute Myeloid Leukemia Key Companies
14 Acute Myeloid Leukemia Key Products
15 Acute Myeloid Leukemia Unmet Needs
16 Acute Myeloid Leukemia Market Drivers and Barriers
17 Acute Myeloid Leukemia Future Perspectives and Conclusion
18 Acute Myeloid Leukemia Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Acute Myeloid Leukemia drugs and therapies- https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:

Acute Myeloid Leukemia Market https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Myeloid Leukemia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Acute Myeloid Leukemia Epidemiology https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Acute Myeloid Leukemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.